Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Ichnos Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis At The 2021 SID Virtual Meeting

              Contact the Supplier

              Lead Product(s): Telazorlimab

              Therapeutic Area: Dermatology Product Name: ISB 830

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 03, 2021

              Details:

              The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.

              PharmaCompass__DigitalAd